OBI Pharma announced FDA clearance of its IND application for OBI-902, a novel TROP2-targeting antibody-drug conjugate utilizing their proprietary GlycOBI® technology platform, with patient enrollment for Phase 1/2 trials expected in the second half of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.